FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could
2023-11-01 07:58
Amgen gets US FTC's go-ahead for $27.8 billion Horizon deal
By Manas Mishra and David Shepardson (Reuters) -The U.S. Federal Trade Commission has allowed Amgen to go ahead with its
2023-09-01 22:57
FTC effort to stop Amgen's Horizon takeover faces uphill fight
By Diane Bartz WASHINGTON The Federal Trade Commission (FTC) faces an uphill battle in its fight against Amgen
2023-05-18 23:19